NZ564732A - Regulation of cytotrophoblast cell differentiation and cell migration - Google Patents
Regulation of cytotrophoblast cell differentiation and cell migrationInfo
- Publication number
- NZ564732A NZ564732A NZ564732A NZ56473202A NZ564732A NZ 564732 A NZ564732 A NZ 564732A NZ 564732 A NZ564732 A NZ 564732A NZ 56473202 A NZ56473202 A NZ 56473202A NZ 564732 A NZ564732 A NZ 564732A
- Authority
- NZ
- New Zealand
- Prior art keywords
- igf
- human
- cytotrophoblast
- cells
- tgf
- Prior art date
Links
- 210000002993 trophoblast Anatomy 0.000 title description 127
- 230000033228 biological regulation Effects 0.000 title description 9
- 230000024245 cell differentiation Effects 0.000 title description 5
- 230000012292 cell migration Effects 0.000 title description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims abstract description 175
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims abstract description 170
- 201000011461 pre-eclampsia Diseases 0.000 claims abstract description 22
- 238000002513 implantation Methods 0.000 claims abstract description 17
- 208000000995 spontaneous abortion Diseases 0.000 claims abstract description 16
- 206010000234 Abortion spontaneous Diseases 0.000 claims abstract description 13
- 208000015994 miscarriage Diseases 0.000 claims abstract description 13
- 239000002243 precursor Substances 0.000 claims abstract description 12
- 230000002269 spontaneous effect Effects 0.000 claims abstract description 10
- 208000009206 Abruptio Placentae Diseases 0.000 claims abstract description 9
- 201000008532 placental abruption Diseases 0.000 claims abstract description 9
- 230000000306 recurrent effect Effects 0.000 claims abstract description 9
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims abstract description 7
- 208000030941 fetal growth restriction Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000035935 pregnancy Effects 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 36
- 210000001161 mammalian embryo Anatomy 0.000 claims description 18
- 230000028742 placenta development Effects 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 108
- 108010009583 Transforming Growth Factors Proteins 0.000 description 108
- 102000005962 receptors Human genes 0.000 description 91
- 108020003175 receptors Proteins 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 65
- 230000027455 binding Effects 0.000 description 47
- 210000002826 placenta Anatomy 0.000 description 47
- 238000011282 treatment Methods 0.000 description 45
- 230000003169 placental effect Effects 0.000 description 39
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 34
- 230000000694 effects Effects 0.000 description 25
- 230000004913 activation Effects 0.000 description 24
- 102000013275 Somatomedins Human genes 0.000 description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 229910052760 oxygen Inorganic materials 0.000 description 22
- 239000001301 oxygen Substances 0.000 description 22
- 230000004069 differentiation Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 230000009545 invasion Effects 0.000 description 18
- 210000003785 decidua Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000004696 endometrium Anatomy 0.000 description 16
- 230000001617 migratory effect Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000008774 maternal effect Effects 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 13
- 238000013508 migration Methods 0.000 description 13
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 12
- 230000005012 migration Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 230000006399 behavior Effects 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 210000002257 embryonic structure Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 102000013566 Plasminogen Human genes 0.000 description 8
- 108010051456 Plasminogen Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000011712 cell development Effects 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000008775 paternal effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 230000002028 premature Effects 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000003228 microsomal effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000035223 Gestational Weight Gain Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 4
- 208000037397 Fetal Weight Diseases 0.000 description 4
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 4
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 230000004709 cell invasion Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000001589 microsome Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 2
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000000056 copulatory effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 2
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 102000038460 IGF Type 2 Receptor Human genes 0.000 description 1
- 238000003744 In vitro fertilisation Methods 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102400000401 Latency-associated peptide Human genes 0.000 description 1
- 101800001155 Latency-associated peptide Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036364 Normal newborn Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000011276 addition treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910001588 amesite Inorganic materials 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000057877 human IGF2 Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 101150088250 matK gene Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed is the use of one or more of IGF-II, a precursor of IGF-II, an isomer of IGF-II, and an analogue of IGF-II in the preparation of a medicament for administration to a female human to prevent and/or treat one or more of implantation failure, recurrent spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and placental abruption.
Description
<div id="description" class="application article clearfix">
<p lang="en" class="printTableText">'21. DEC. 2007 1 5:54 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P. 6/53 <br><br>
Patent Form No. 5 564732 <br><br>
NEW ZEALAND <br><br>
Patents Act 1953 <br><br>
*10055390082* <br><br>
COMPLETE SPECIFICATION <br><br>
DIVISIONAL OF NEW ZEALAND PATENT APPLICATION 531362 <br><br>
TITLE: REGULATION OF CYTOTROPHOBLAST CELL DIFFERENTIATION AND CELL <br><br>
MIGRATION <br><br>
We The University of Adelaide, of North Terrace, Adelaide, South Australia, 5000, Australia, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: rTTco-rvl <br><br>
OFFICE OF <br><br>
2 \ 0EC 2007 <br><br>
KlOSH <br><br>
REC£W <br><br>
f D <br><br>
"21. DEC. 2007"!5:54 ~ PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P.^ 7/53 <br><br>
la <br><br>
Regulation Of Cytotrophoblast Cell Differentiation And Cell Migration FIELD OF THE INVENTION <br><br>
The present invention relates to the use of a method to adjust the behaviour of cytotrophoblast cells of the placenta and that of stem cells. In particular the invention is 5 concerned with the regulation of their differentiation and migration. <br><br>
BACKGROUND OF THE INVENTION <br><br>
During embryo implantation and placentation. cytotrophoblast cells of the conceptus proliferate and migrate. Growth factors induce cytotrophoblasts to replicate, and to increase the number of cytotrophoblasts that migrate into the uterine endometrium. 10 During this process cytotrophoblasts sequentially attach (adhere) and detach (de- <br><br>
adhere) from surrounding cells and extracellular matrix. Migrating cytotrophoblasts also secrete extracellular matrix to which they can adhere, as well as proteolytic enzymes that degrade the extracellular matrix from which they detach and through which they migrate. Similar processes occur during differentiation of stem cells in the embryo, 15 fetus, child, and adult. <br><br>
In many biological processes, cells change or differentiate from one ceil type to another in response to growth factor polypeptides and glycoproteins. In mammals, these growth factors may either originate from the progenitor cell undergoing differentiation (autocrine mechanism) or from neighbouring cells (paracrine mechanism). These 20 biological processes include those that occur during normal mammalian development in which cells of different types in the conceptus change into other cell types that form the placenta, tissues and organs of the embryo, the fetus, and eventually the adult. <br><br>
The differentiation pathway of cytotrophoblasts and embryonic and adult stem cells includes migration from one site to another. This can include invasion by the migrating 25 celts into a tissue or organ comprised of or constructed by cells of other types or lineages. <br><br>
Cells of all types proliferate and migrate during organogenesis and to increase the size of the tissue during normal development and growth in embryonic/fetal life and throughout childhood. <br><br>
'21. DEC. 2007"15:54 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. <br><br>
2 <br><br>
Embryonic stem cells are pluripotent cells derived from the inner cell mass of the early mammalian embryo from which all cell types of the embryo and all endodermal and mesodermai cells in the extra-embryonic tissues are derived. In vivo they differentiate in a low oxygen environment during the first third of pregnancy in humans and other 5 mammals. <br><br>
Adult stem cells are pluripotent cells found in all mammalian tissues firom which many or all cell lineage types of the body may differentiate. <br><br>
Cytotrophoblast cells are derived from extra-embryonic ectodermal cells of the conceptus, which comprise the trophectoderm of the blastocyst, Cytotrophoblast ceils 10 are therefore an epithelial cell type. Cytotrophoblast cells migrate into the endometrium of the maternal uterine decidua to form the placenta. Within the exchange region of the placenta cytotrophoblast cells, known as villous cytotrophoblasts, retain their epithelial phenotype. However, invasive cytotrophoblasts, also known as extravillous cytotrophoblasts, have undergone epithelial-mesenchymal transition, a process which 15 allows them to assume a migratory phenotype. Invasion of the maternal decidua by cytotrophoblast cells is terminated by fusion of cytotrophoblast cells to form multinucleate cells called placental bed giant cells. <br><br>
Under specific conditions cytotrophoblasts and stem cells, both embryonic and adutt, are able to syntheslse and secrete insulin-like growth factor II (IGF-H). These processes 20 occur in a low oxygen environment. <br><br>
Since the IGF-II gene is imprinted and expressed by the paternal allele, the paternal genotype Is important In determining the capacity of the placenta, the genotype of which is a combination of the paternal and maternal_ genotypes, to syntheslse IGF-H, It is known that there are polymorphisms in the IGF-H gene which may determine the 25 capacity of tissues to synthesise IGF-II. Since the placenta synthesises abundant IGF-II it was postulated that mutations in the /GF-// gene may lead to pre-eclampsia, A common Apa I restriction fragment length polymorphism in exon 9 of the IGF-H gene was investigated as a possible mutation which causes pre-eclampsia (Bermingham et al. 2000). It was unequivocally shown that this polymorphism in the IGF-l! gene is not 30 involved in pre-eclampsia. The authors concluded that IGF-II does not play a role in the aetiology of pre-eclampsia. As there are other polymorphisms in this gene and neighbouring genes which determine the capacity of the placenta to synthesise IGF-II, <br><br>
21. DEC. 2007 15:55 <br><br>
PHILLIPS ORMONDE k FITZPATRICK <br><br>
NO. 1 846 P. 9/53 <br><br>
3 <br><br>
and hence its capacity to invade the uterine decidua and establish optimal placenta function, we claim that IGF-II plays a determining role in pre-eclampsia. <br><br>
Expression of IGF-II is affected by a functional polymorphism of the insulin (INS) variable 5 number of tandem repeats (VNTR) locus in humans. In Caucasians, the WSVNTR micro satellite divides into two classes of alleles which vary in size. Class 1 alleles (26-63 repeat units) have been strongly associated with insulin dependent diabetes mellitus (Bennett & Todd1996), while Class 111 alleles protect against IDDM but are associated with non-insulin dependent diabetes mellitus (Ong et at. 1999). The //VSVNTR has been shown to be a long range control 10 element for both insulin and IGF-II. <br><br>
All nucleated cells in the body have the capacity to detect oxygen concentration and respond accordingly. Chronic reductions in oxygen concentration within the cell result in new gene expression which is mediated by several transcription factors. Hypoxia inducible factor -1 (H(F-15 1) Is an oxygen-sensitive transcription factor which regulates gene expression in response to low cellular oxygen concentration. HIF-1 activates the transcription of a variety of target genes whose protein products are involved in angiogenesis, cell proliferation and viability, and vascular remodelling. HIF-1, also known as ARNT, is constitutively expressed and must bind to HIF-1, which is regulated by hypoxia (Huang et al. 1996), before binding to DNA as a heteromeric 20 complex (Wang et al. 1995). IGF-II is a target gene for HIF-1 and is thought to be both regulated by, and a regulator of, HIF-1 (Feldser et al. 1999). Feldser et al. reported that in normoxic conditions insulin, IGF-I and IGF-II all induce HIF-1 protein expression resulting in transcription of its target genes including IGF-II, IGFBP-2 and IGFBP-3. When human chorionic villous explants were cultured in 2% O2 and compared with those cultured in 20% O2 cytotrophoblast 25 proliferation was increased nearly 3-fold (Genbacev et al. 1997). In cultured human villous explants HIF-1 transcription was stimulated by low oxygen tension (3% O2) and cytotrophoblast proliferation ensued (Caniggia et al, 2000). <br><br>
A reference herein to a patent document or other matter which is given as prior art is not to be 30 taken as an admission that that document or matter was, in New Zealand, known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims. <br><br>
Throughout the description and claims of this specification, the word" comprise" and 35 variations of the word, such as" comprising" and" comprises" , is not intended to exclude other additives, components, integers or steps. <br><br>
21. DEC. 2007"15:55 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P. 10/53 <br><br>
3a <br><br>
SUMMARY OF THE INVENTION <br><br>
In one aspect, the present invention provides use of one or more of IGF-II, a precursor of IGF-ll, an isomer of IGF-II, and an analogue of IGF-II in the preparation of a medicament for 5 administration to a female human to prevent and/or treat one or more of implantation failure, recurrent spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and placental abruption. <br><br>
In another aspect, the present invention provides a method of promoting implantation of a non-10 human embryo in a non-human female mammal and/or promoting placentation in a non-human female mammal, the method including administering to the female mammal an effective amount of one or more of IGF-ll, a precursor of IGF-H, an isomer of IGF-II, and an analogue of IGF-II. <br><br>
In another aspect the present invention provides a method of preventing and/or treating one or 15 more of implantation failure, recurrent spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and plaoental abruption in a non-human female mammal, the method including administering to the non-human female mammal an effective amount of one or more of iGF-ll, a precursor of IGF-II, an isomer of IGF-II, and an analogue of IGF-H. <br><br>
20 In another aspect the present invention provides a method of improving one or more of placental formation, placental growth, placental development, placental differentiation and placental function in a female mammal, the method including exposing an embryo for implantation into the female mammal to an effective amount of one or more of IGF-II, a precursor of IGF-II, an isomer of IGF-II, and an analogue of IGF-II, <br><br>
25 <br><br>
In another aspect, the present invention provides a method of diagnosing the ability of a female mammal to establish and/or sustain a successful pregnancy, the method including determining the composition and/or sequence of nucleotides in and/or near the IGF-ll gene in a biological sample obtained from the female mammal so as to determine the extent of IGF-II production in 30 the female mammal, wherein a deficiency in IGF-H production is indicative of an inability of the female mammal to establish and/or sustain a successful pregnancy. <br><br>
35 <br><br>
21. DEC, 200715:55 PHILLIPS ORMONDE 4. FITZPATRICK <br><br>
NO. 1846 P. 11/53 <br><br>
3b <br><br>
In another aspect, the present invention provides a method of diagnosing of the ability of a paternal male mammal to establish and/or sustain a successful pregnancy in a female mammal, the method including determining the composition and/or sequence of nucleotides in and/or near the IGF-II gene in a biological sample obtained from the male mammal so as to determine 5 the extent of IGF-II production in the male mammal, wherein a deficiency in IGF-II production in the male mammal is indicative of an inability of the paternal male mammal to establish and/or sustain a successful pregnancy in a female mammal. <br><br>
In another aspect the present invention provides a method of diagnosing the ability of a 10 mammalian embryo to establish and/or sustain a successful pregnancy, the method including determining the composition and/or sequence of nucleotides in and/or near the IGF-II gene in a biological sample from the embryo so as to determine the ability of the embryo to produce IGF-II, wherein a deficiency in IGF-II production in the embryo is indicative of an inability of the embryo to establish and/or sustain a successful pregnancy. <br><br>
15 <br><br>
In another aspect the present invention provides a method of diagnosing the ability of a female mammal to establish and/or sustain a successful pregnancy, the method including determining the amount of IGF-II circulating in a blood sample obtained from the female mammal, wherein a deficiency in IGF-II level in the blood is indicative of an inability of the female mammal to 20 establish and/or sustain a successful pregnancy. <br><br>
In another aspect the present invention provides a method of diagnosing the ability of a paternal male mammal to establish and/or sustain a successful pregnancy in a female mammal, the method including determining the amount of IGF-lt circulating in a blood sample obtained from 25 the paternal male mammal, wherein a deficiency in IGF-II level in the blood is indicative of an inability of the paternal male mammal to establish and/or sustain a successful pregnancy in a female mammal. <br><br>
21. DEC. 2007 15:56 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. <br><br>
12/53 <br><br>
3c <br><br>
In another aspect the present invention provides a method of in vitro regulating proteolytic conversion of latent TGF-p1 to active TGF-01 by CIM6P receptor expressed on a cell, the method including modulating binding of K3F-II to the CIM6P receptor expressed on the cell and thereby regulate the conversion of latent TGF-pi to active TGF-|J1. <br><br>
The present invention is predicated on the discovery of certain interactions between cellular growth factors and opposing actions that control differentiation and migration or invasion of cytotrophoblasts into the uterine endometrium which, during pregnancy, is <br><br>
'21. DEC. 2007 1 5:56' <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 13/53 <br><br>
4 <br><br>
called the decidua. In addition, this discovery may be applied to embryonic or adult stem cells to control their differentiation and migratory behaviour. <br><br>
Therefore, according to a first aspect of the present invention, although this need not be the broadest nor indeed the only aspect of the invention there is provided a method of 5 regulating cytotrophoblast and stem cell differentiation and migration consisting of adjusting levels of IGF-II available for binding to the cation-independent mannose-6-phosphate (CIM6P) receptor. <br><br>
We have discovered that IGF-II and latent transforming growth factor beta (TGF ), the inactive precursor of TGF , compete for binding to the CIM6P receptor. IGF-ll prevents 10 latent TGF binding to the CIM6P receptor. It is known that binding of latent TGF to the CIM6P receptor leads to the production of active TGF by the urokinase plasminogen activator (uPA) system (Godar et al. 1699). It is suggested that IGF-ll prevents activation of latent TGF . Cells that produce sufficient amounts of IGF-II, or cells that are exposed to sufficient amounts of IGF-ll, therefore cannot convert latent 15 TGF into its active form (TGF ) by the uPA system that forms a complex with the CIM6P receptor on the surface of the cell. <br><br>
The present invention therefore offers a method of regulating and directing cytotrophoblast differentiation and function based on the interaction between IGF-ll, latent TGF and the CIM6P receptor. <br><br>
20 During pregnancy In humans, IGF-II is produced by cytotrophoblast cells and is most abundantly expressed at the invasive front. It is known that TGF promotes terminal differentiation in these cells, thus inhibiting their migratory behaviour. <br><br>
We have discovered that IGF-II binding to the CIM6P receptor prevents local activation of TGF . In cytotrophoblast cells, IGF-ll thereby prevents migratory or invasive 25 mesenchymal-type cytotrophoblast cells from differentiating into non-migratory or noninvasive giant cell types. <br><br>
Competition for binding the CIM6P receptor is dependent on the concentration of IGF-II and the concentration of latent TGF in the vicinity of cytotrophoblasts. The GIM6P receptors on the surface of cytotrophoblasts that produce sufficient quantities of IGF-II 30 or are exposed to sufficient amounts of IGF-II are unable to bind latent TGF . In this <br><br>
21. DEC. mi <br><br>
15:56 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 14/53 <br><br>
5 <br><br>
way IGF-II prevents cytotrophoblasts from activating latent TGF . in the presence of sufficient IGF-II these cells therefore maintain their mesenchymal type and migratory activity. <br><br>
Removal of IGF-ll permits these cells to activate latent TGF . The action of TGF 5 converts these cells into non-repllcating and non-migratory types. <br><br>
It will be appreciated that in the placenta the promotion of cytotrophoblast migration is highly desirable. It will also be appreciated that the application of stem cell technology to treat disease may require promotion of epithelial-mesenchymal transition or its inhibition depending on the direction of stem cell differentiation required. <br><br>
10 Thus, in a first preferred form of the invention there is provided a method of promoting invasive and migratory cell behaviour by exposing cytotrophoblasts or stem cells (embryonic or adult) to elevated levels of IGF-II, such that the cell CIM6P receptors are unable to bind latent TGF/?. <br><br>
In reproduction treatment with insulin-like growth factor ll (IGF-II) promotes implantation 15 and placentation: <br><br>
Insulin-like growth factor II treatment of embryos promotes conversion of trophectoderm ceils into cytotrophoblast cells thereby increasing the success of implantation of embryos into the uterine decidual endometrium, thereby increasing the success of formation of a viable placenta, and thereby improving the rate of successful pregnancy. <br><br>
20 Addition of insulin-like growth factor li to embryos produced by in vitro fertilisation techniques can be used to treat infertility. Thus, treatment of pregnant women or their embryos with insulin-like growth factor II can be used to prevent recurrent spontaneous miscarriage and to prevent pre-eclampsla. <br><br>
Further, administration of IGF-ll to pregnant women or their embryos may prevent 25 intrauterine growth restriction or be used to treat placental abruption. <br><br>
Treatment of embryonic stem cells or adult stem ceils with insulin-like growth factor II or culture in a hypoxic environment (1% oxygen) which increases their synthesis of insulin-like growth factor II, promotes their differentiation into mesodermal/mesenchymal cell types. <br><br>
21. DEC. 2007" 15:56 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P. 15/53 <br><br>
6 <br><br>
In a further form of the invention there is provided a method of inhibiting stem ceil division, stern cell migration and promoting terminal differentiation behaviour by exposing said stem ceil to reduced levels of IGF-II, such that the stem cell CIM6P receptors are able to bind latent TGF/? and thereby promote the activation of TGF/?. <br><br>
5 Thus, treatment of embryonic stem cells or adult stem cells with inhibitors of IGF-II action on CIM6P receptor (for example soluble CIM6P receptor or fragments thereof) <br><br>
will promote their differentiation into epithelial cell types, including neurones or their precursors. <br><br>
The invention is, in a further aspect exemplified by the use of not only IGF-II in its basic 10 form, but also to naturally occurring precursors of and isomers of IGF- IK Similarly, the treatments identified above may be carried out also using synthetic analogues of IGF-II that have altered ability to bind to type-1 IGF receptors, altered ability to bind to insulin receptors, altered ability to bind to IGF-binding proteins and increased ability to bind to cation-independent mannose-6-phosphate receptors (also known as CIM6P receptors, 15 type-2 IGF receptors and IGF-II receptors). <br><br>
Still further aspects of the invention are concerned with diagnostic uses of IGF-ll and the recognition that variation in the capacity of the placenta to produce IGF-II allows predictions to be made concerning the differentiation/migration behaviours to be expected from cytotrophoblasts and therefore the capacity of the placenta to sustain a 20 healthy pregnancy. <br><br>
Thus, in accordance with a still further aspect of the invention measurement of the composition of and the sequence of nucleotides in the deoxyribonucleic acid near the insulin-like growth factor II gene in human embryos can be used to diagnose their ability to establish successful healthy pregnancy, in particular, the sequence of 25 nucleotides known as the insulin (INS) variable number of tandem repeats (VNTR), which is known to determine placental production of IGF-II, specifically determines the capacity of cytotrophoblasts to synthesize IGF-II and hence determines their capacity to migrate into the uterine decidua and therefore determines the capacity of the placenta to transport substrates to the embryo/fetus. <br><br>
30 Alternatively, determination of the nucleotide sequence of the same gene locus INS VNTR on biological specimens (for example blood) from both the mother and the father can be used to diagnose their ability to establish successful healthy pregnancy. <br><br>
21. DEC. 2007 15:57 PHILLIPS ORMONDE & FITZPATRICK NO. 1846 P. 16/53 <br><br>
7 <br><br>
Similarly, measurement of the amount ot messenger ribonucleic acid transcribed Irom the insulin-like growth factor II gene in human embryos can be used to diagnose their ability to establish successful healthy pregnancy. <br><br>
Measurement of the amount of insulin-like growth factor II protein secreted by human 5 embryos can also be used to diagnose their ability to establish successful healthy pregnancy. <br><br>
The measurements as described above may be performed on a specimen obtained from either or both biological parents of a human embryo and can be used to diagnose their ability to establish successful healthy pregnancy. This information can thus be 10 used to assist in identifying those individuals who are likely to derive most benefit from treatment according to the methods of the invention. <br><br>
It should be noted that the methods of the invention may be used in humans as well as in other mammalian species, such as the horse, cow, sheep, goat and pig. <br><br>
The action of IGF-II in regulating cytotrophoblast differentiation/migration is provided 15 below. IGF-ll is produced by cytotrophoblast cells. These cells are known to have receptors able to bind IGF-ll (Rebourcet et al. 1998),. These receptors include type-1 IGF receptors, which bind IGF-I, IGF-II and insulin. In many cell types, binding of IGF-I, IGF-II or insulin to the type-1 IGF receptor promotes cell division, also alternatively known as mitosis, replication, multiplication or proliferation. <br><br>
20 Cytotrophoblast cells have another receptor type that binds IGF-II very well, binds IGF-I extremely poorly and does not bind insulin. This receptor has been called the lype-2 IGF receptor (Rebourcet et al. 1998). This receptor also binds certain glycoproteins that contain mannose-6-phosphate and has also been called the cation-independent mannose-6-phosphate (CIM6P) receptor. We have discovered that competition 25 between IGF-II and latent TGF for binding to the CIM6P/lype-2 IGF receptor underlies the action of IGF-ll in regulating the ability of cytotrophoblasts to undergo migratory or non-migratory behaviours in any environment. <br><br>
In the human placenta, IGF-ll is most abundantly produced by cytotrophoblast cells that have migrated furthest into the maternal decidual endometrium (Guidice et al. 1098; 30 Irwin et al. 1999), IGF-II promotes migration of cytotrophoblast cells by a mechanism that has hitherto been unknown (Hamilton et al, 1998). <br><br>
21. DEC. 2007 15:57 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 17/53 <br><br>
8 <br><br>
Cytotrophoblast cells have TGF receptors able to bind TGF (Schilling & Yeh 2000). Treatment of cytotrophoblast cells with TGF promotes their fusion to form non-migratory multinucleate giant cells (Morrish et al. 1 998). <br><br>
Active TGF , capable of binding to TGF receptors, is derived by proteolytic conversion 5 from inactive latent TGF , which does not bind to TGF receptors. Latent TGF is produced by maternal uterine decidual cells and by cytotrophoblast cells (Graham & <br><br>
Lala 1991). <br><br>
Latent TGF is known to bind to the CIM6P receptor. Latent TGF can also bind to CIM6P receptors that are associated in a complex with plasminogen and urokinase 10 plasminogen activator (uPA) receptors. <br><br>
It is known that uPA converts latent TGF into active TGF by the catalytic action of uPA when bound to the complex formed by the simultaneous association of uPA receptor, plasminogen and latent TGF with the CIM6P receptor (Godar et al. 1999). Cytotrophoblast cells are known to have uPA receptors (Floridon et al. 1999). <br><br>
15 It has been suggested that binding of IGF-II to the CIM6P receptor is a mechanism that removes and degrades IGF-II. The CIM6P receptor competes with the type-1 IGF receptor for IGF-If binding. IGF-ll binding to the type-1 IGF receptor promotes cell division and replication. According to the prior art, the CIM6P receptor reduces the amount of IGF-ll able to bind to the type-1 IGF receptor and thus reduces the ability of 20 cells to proliferate or replicate In response to IGF-II. Thus, the CIM6P receptor by competing with the type-1 IGF receptor prevents IGF-II from promoting cell replication. According to the prior art, IGF-ll binding to the C1M6P receptor does not produce a direct biological response within the cell upon whose surface the CIM6P receptor is located (Odeii & Day 1998). <br><br>
25 There is an additional body of evidence that shows that activation of latent TGF occurs on CIM6P receptors located on the cell surface and that this is dependent on simultaneous binding of the uPA/plasminogen system (Godar et al. 1999). <br><br>
However, it has hitherto not been recognised that IGF-II and latent TGF compete for binding at the same site on CIM6P receptors and that their competition for binding 30 regulates the amount of active TGF formed by this receptor complex and therefore the <br><br>
'21. DEC, 2007"" 15:57" <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 18/53 <br><br>
9 <br><br>
amount of active TGF available to its specific receptors on the cytotrophoblast cell surface. We have discovered that competition between IGF-II and latent TGF for the CIM6P receptor occurs and that IGF-ll inhibits activation of latent TGF and that this is therefore a mechanism for the regulation of cytotrophoblast differentiation and 5 migration. Inhibition of TGF signalling has been shown to promote differentiation of embryonic stem cells into neural stem cells (Tropepe et al. 2001). Therefore alteration of the concentration of IGF-II in the local environment of stem cells will control how much latent TGF is activated and therefore will determine whether these cells differentiate along an epithelial (decreased IGF-II) or mesenchymal or migratory 10 (increased IGF-II) pathway. <br><br>
DESCRIPTION OF DRAWINGS <br><br>
Figure 1 shows schematically the mechanism by which IGF-II binding to the CIM6P receptor permits cytotrophoblast Invasion of the decidua; <br><br>
Figure 2 Illustrates the effect of IGFs on activation of TGF by human TF1 monocytes; <br><br>
15 Figure 3 illustrates the effect of oxygen on the number of outgrowing tips from human placental villous explants which formed cytotrophoblast cell columns; <br><br>
Figure 4 Illustrates the effect of oxygen on IGF-II mRNA expression by human placental villous explants at 7.5-8 weeks gestation; <br><br>
Figure 5 illustrates the effect of treatment with IGF-II between days 2 and 10 of 20 pregnancy In the mouse on placental weight at day 18; <br><br>
Figure 6 illustrates the effect of treatment with IGF-II between days 2 and 10 of pregnancy in the mouse on the distribution of placental weights at day 18; <br><br>
Figure 7 illustrates the effect of treatment with IGF-II between days 2 and 10 of pregnancy in the mouse on fetal weight at day 18; <br><br>
" 25 Figure 8 illustrates the effect of treatment with IGF-II between days 2 and 10 of pregnancy in the mouse on the distribution of fetal weights at day 16; <br><br>
Figure 9 illustrates the effect of treatment with IGF-II between days 2 and 18 of pregnancy in the mouse on placental weight at day 18; <br><br>
21. DEC. 20G7"15:57 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 19/53 <br><br>
10 <br><br>
Figure 10 illustrates the effect of treatment with IGF-ll between days 2 and 18 of pregnancy in the mouse on placental thickness at day 18; <br><br>
Figure 11 illustrates the effect of treatment with IGF-II between days 2 and 18 of pregnancy in the mouse on the distribution of fetal weights at day 18; <br><br>
5 Figure 12 illustrates the effect of treatment with IGF-ll between days 2 and 18 of pregnancy In the mouse on the distribution of placental weights at day 18; and <br><br>
Figure 13 illustrates the effect of treatment with IGF-II between days 2 and 18 of pregnancy in the mouse on the ratio of fetal to placental weights at day 18. <br><br>
DESCRIPTION OF THE PREFERRED EMBODIMENT <br><br>
10 The discovery of the interaction of IGF-II and TGF with the CIM6P receptor can be applied by the use of IGF-II in early pregnancy to treat both implantation failure and recurrent spontaneous miscarriage. <br><br>
During pregnancy cytotrophoblast cells that are originally derived from the trophectoderm of the blastocyst and which subsequently form the placenta remodel the 15 endometrium. .The placenta is the active interface between maternal and fetal tissues and is the organ through which exchange of soluble materials between fetus and mother occurs. <br><br>
The embryo establishes its attachment with the endometrium through the actions of migratory cytotrophoblast cells known as extravillous cytotrophoblasts. They secrete 20 metalloproteinases that degrade the extracellular matrix of the endometrium, permitting their invasion. These Invasive cells modify the endometrial spiral arterioles to provide access for the placenta to the maternal blood supply, the source of all matter for embryonic and fetal growth. Cytotrophoblast cells form columns that extend deep into the endometrium. The first wave of invasion of the endometrium by cytotrophoblast 25 cells occurs between 6 and 12 weeks of pregnancy in humans (Pijnenborg et al. 1963). This is the period when most miscarriages occur. It is also the period in which there is no maternal blood flow Into the placenta such that cytotrophoblasts proliferate and differentiate in a hypoxic environment. IGF-II is abundantly produced eariy in pregnancy by cytotrophoblast cells at the leading edge of the invasive front of the cell column. IGF-30 II promotes the invasive behaviour of cytotrophoblast cells. Latent TGF is produced by decidual cells of the maternal endometrium as well as by cytotrophoblast cells. TGF <br><br>
"21. DEC. 2007 15:58 PHILLIPS ORMONDE & FITZPATRICK NO. 1846 P. 20/53 <br><br>
11 <br><br>
promotes fusion of cytotrophoblast cells, an essential step in their differentiation to form mature components of the placenta (Morrish et al. 1998). TGF also induces synthesis and secretion of tissue inhibitors of rnetalloproteinases (TIMPs) by cytotrophoblast cells (Lala & Graham 1990), thus preventing cytotrophoblast cells from degrading the 5 extracellular matrix necessary for their migration. <br><br>
We hypothesise that early pregnancy loss due to failure to establish a viable placenta is caused by IGF-ll deficiency in the IGF-ll/TGF /CIM6P receptor system of cytotrophoblasts, Further, it appears that failure of the embryo to successfully implant into the uterine endometrium of the mother is due to insufficient production of IGF-ll by 10 cytotrophoblast cells derived from the irophectoderm of the blastocyst, leading to reduced autocrine stimulation of invasion of the endometrium by cytotrophoblast cells. Thus, removal or lack of IGF-II induces terminal differentiation and fusion of cytotrophoblasts. <br><br>
Spontaneous miscarriage (diagnosed between the 6th and 12th weeks of pregnancy) 15 may thus be caused by deficiency in IGF-II production of cytotrophoblast cells leading to premature fusion before sufficient colonisation of the endometrial decidua has been achieved to establish a healthy placenta. Accordingly, IGF-II can be used to treat both implantation failure and recurrent spontaneous miscarriage. <br><br>
Impaired cytotrophoblast invasion of the uterine decidua is associated with pre-20 eclampsia, a common hypertensive disorder of pregnancy which is life-threatening in 3% of pregnancies in developed nations. It follows that deficiency of IGF-ll synthesis by extravillous cytotrophoblasts results in reduced invasive behaviour, poor placentation and pre-eclampsia, TGF hss also been associated with pre-eciampsia as women who develop this disease have elevated concentrations of active TGF 1 in their blood 25 (Djurovic et al. 1997). We claim that this is a result of insufficient IGF-II to maintain activation of TGF at normal levels. <br><br>
We have discovered that IGF-II and latent TGF , the precursor of TGF , compete for binding to CIM6P receptors in human placenta. Latent TGF binding to C1M6P receptor is known to lead to Its proteolytic conversion by plasmin into active TGF by the 30 complex formed between urokinase plasminogen activator (uPA), uPA receptor and plasminogen (Godar et al. 1999). It is known that cytotrophoblast cells have CIM6P receptors (Rebourcet et al. 199B) and uPA receptors (Floridon et al. 1999). It follows <br><br>
'21. DEC. 2007"15:58~ PHILLIPS ORMONDE & FITZPATRICK NO. 1 846 P. 21/53 <br><br>
12 <br><br>
from our discovery that secretion of IGF-ll by cytotrophoblast cells maintains their invasive state by preventing local activation of TGF , the initiator of their terminal differentiation into non-replicating and non-migratory cells. It is known that invasive cytotrophoblast cells produce IGF-ll in abundance (Irwin et al. 1999). <br><br>
5 We show herein that IGF-II and latent TGF compete for binding to the placental <br><br>
CIM6P receptor. It is known that activation of TGF from its latent form is a prerequisite for its promotion of cytotrophoblast cell fusion and terminal differentiation. It has been discovered that IGF-II inhibits terminal differentiation of cytotrophoblast cells and, that this is the means by which IGF-II promotes cytotrophoblast cell invasion of the decidua. <br><br>
10 In figure 1 the mechanism by which IGF-ll promotes cytotrophoblast invasion of the decidua is shown. In (A) IGF-II inhibits binding of latent TGF to the receptor and permits the simultaneous activation of matrix rnetalloproteinases by plasmin produced by the action of uPA on plasminogen secreted by cytotrophoblasts to facilitate their migration into the uterine decidua. (B) When latent TGF binds the CIM6P receptor, IS plasmin that is generated as above is available to cleave the latency associated peptide from latent TGF resulting in activation of TGF which may then bind its specific receptors at the cell surface and induce cytotrophoblast terming} differentiation. <br><br>
In accordance with our discovery that IGF-ll and TGF0 compete for CIM6P binding, we have also discovered that during placental development, CIM6P receptor-bound IGF-II 20 maintains cytotrophoblast cell type and promotes degradation of extracellular matrix essential for invasion of the endometrium by cytotrophoblast cells. Binding of latent TGF to the same CIM6P receptor, in preference to IGF-II, activates TGF which initiates cytotrophoblast differentiation into a non-migratory cell type and promotes fusion into multinucleate placental bed giant cells. Thus, it is suggested that early 25 pregnancy loss is characterised by Inadequate IGF-ll synthesis or premature reduction or cessation of IGF-ll synthesis and secretion by extravillous cytotrophoblast cells, which allows binding of latent TGF to their C1M6P receptors. Deficiency in IGF-ll results in premature activation of TGF by the uPA system complexed to the CIM6P receptor. We claim that premature activation of TGF is a consequence of IGF-ll 30 deficiency in cytotrophoblast cells. Active TGF then promotes premature fusion of cytotrophoblast cells. This reduces the numbers of invading extravillous cytotrophoblast celis below critical levels required to form a placenta that can sustain adequate extraction of oxygen and nutrients from the utero-placental blood supply for use by the <br><br>
'21. DEC. 2007*1 5:58 PHILLIPS ORMONDE & FITZPATR1CK <br><br>
NO. 1846 <br><br>
P. 22/53 <br><br>
13 <br><br>
placenta and the embryo and fetus. The placenta necroses and miscarriage ensues. We claim that IGF-ll delivered to the implantation site promotes extravillous cytotrophoblast cell invasion. <br><br>
As normal pregnancy advances, cytotrophoblast cells become progressively exposed 5 to increasing amounts of both oxygen and maternal adrenal glucocorticoids. It is known that both oxygen and glucocorticoids inhibit production of IGF-II by many cell types, <br><br>
This allows more latent TGF to bind to the CIM6P receptor and therefore increases the amount of active TGF produced at the cell surface. Increased exposure to active TGF causes terminal differentiation of cytotrophoblasts into non-replicating, non-10 invasive cells. The timing of premature terminal differentiation of cytotrophoblasts determines the severity of the defect in implantation and placentation. <br><br>
Up to 50% of miscarriages have been attributed to inadequate invasion of the decidua by cytotrophoblast cells (Khong et al. 1987). We claim that reduced IGF-ll production . by cytotrophoblast cells during embryo implantation and in the first weeks of pregnancy 15 causes implantation failure and miscarriage. <br><br>
Pre-eclampsia, a hypertensive disorder that occurs later in pregnancy and is also characterised by impaired cytotrophoblast cell invasion of the decidua (Khong et al. 1986), is, according to our discovery, caused by IGF-II deficiency of cytotrophoblast cells. The effects of impaired cytotrophoblast invasion in the first trimester of pregnancy 20 are not apparent symptomaticaliy in the mother until later. The most severe form of preeclampsia is diagnosed during the middle trimester of pregnancy, while less severe cases are not diagnosed until later in the third trimester. We claim that the more severe forms of pre-eclampsia are characterised by a poor capacity of cytotrophoblast cells to synthesis© IGF-ll and a poor response of these cells to synthesise IGF-II in hypoxic 25 conditions as occur in the first trimester of pregnancy. Less severe forms of preeclampsia are also due to inadequate cytotrophoblast production of IGF-II but their IGF-II response to hypoxia is between that in severe cases and normal pregnancy. <br><br>
A diagnostic test based on cytotrophoblast capacity for IGF-ll synthesis conducted early in pregnancy to identify those at risk of symptoms of pre-eclampsia later in 30 pregnancy would allow early treatment and monitoring by health care providers. It is our discovery that IGF-II can be used to prevent and treat pre-eclampsia by elevating circulating IGF-ll concentrations to the normal pregnancy range which has been <br><br>
"21. DEC. 2007 15:59 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO, 1846 <br><br>
P. 23/53 <br><br>
14 <br><br>
previously shown to be about 2,200ng/ml in pooled serum compared to about 1500-1600ng/ml in the non-pregnant state (Gargosky et al. 1990), <br><br>
Convenient methods of treatment with IGF-II would include the use of subcutaneous delivery devices or extended release vaginal pessaries. A range of other conventional 5 delivery systems would be suitable. Treatment with IGF-II is concerned with raising the maternal blood level of IGF-II to 'normal' levels throughout the pregnancy, that is the treatment is a generally remedial action preferably to be applied in situations where diagnosis has indicated a predicted or measured reduction in IGF-tl levels. The duration of treatment will therefore be specific to each individual concerned. In some 10 cases the treatment may be continued throughout the pregnancy and In other treatment may be required only during the first half of the pregnancy. <br><br>
A less severe font) of impaired cytotrophoblast cell invasion leads to placental abruption (Dommisse & Tiltman, 1992), in which premature separation of the placenta from the decidua occurs in the last weeks of pregnancy, and which requires emergency 15 delivery of the baby, is also due to moderate IGF-ll deficiency of cytotrophoblast cells. IGF-ll can be used to prevent placental abruption. <br><br>
IGF-ll deficiency impairs the ability of cytotrophoblast cells to invade the decidua. The diseases of pregnancy discussed above form a continuum of related disorders that depend on the degree of IGF-ll deficiency and consequently the timing and extent of 20 the reduced invasion of the decidual endometrium by cytotrophoblast cells. <br><br>
Example 1 IGF-ll competes with latent TGF for binding to cation-independent mannose-6-phosphate receptors on human placental microsomal membranes <br><br>
The competition between IGF-II and latent TGF for the CIM6P binding site can be demonstrated as follows: <br><br>
25 Human placenta was obtained from the Women's and Children's Hospital, North Adelaide after delivery of a normal baby following an uncomplicated pregnancy, and used as a source of CIM6P receptors (Owens et al. 1980). A suspension of microsomal membranes was prepared from the placenta by homogenisation and differential ultra-centrifugation (Owens et al. 1980). Human IGF-II and IGF-I (receptor grade) were 30 obtained from GroPep Pty. Ltd. Human latent TGF 1 was purchased from R&D <br><br>
Systems, Inc. IGF-II was radioactively labelled with iodine-125 to a specific activity of <br><br>
21. DEC. 2007 15:59 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P. 24/53 <br><br>
15 <br><br>
70 Ci/g using chloramine-T (Francis el al. 1989). IGF-II labelled in this manner does not bind to lype-1 IGF receptors (Francis et al. 1989). Replicates of 10 g of human placental microsomal protein were simultaneously incubated at 4°C for 20 h in 150 I of 0.05 mol/litre Tris-HCI buffer pH 7.4 containing 1 picomole of iodo-125-lGF-ll, 0.01 5 mol/litre calcium chloride and 5 gram/litre bovine albumin (Owens et al. 1985). Different ■ replicates also contained either IGF-II, IGF-I or latent TGF 1 at a number of different concentrations. Radioactivity bound to human placental microsomal membranes was recovered by centrifugation (Owens et al. 1985). Blank binding of iodo-125-IGF-ll was measured in the absence of human placental microsomes. Non-specific binding of 10 iodo-125-lGF-ll was measured in the presence of unlabeled IGF-II at a concentration of 133 nanomol/litre (Owens et al. 1965). <br><br>
IGF-I, IGF-II and latent TGF 1 inhibited the binding of iodo-125-IGF-ll to human > placental microsomes (Table 1), <br><br>
Unlabeled IGF-II when present at a concentration of 1.6 nanomol/litre inhibited specific 15 binding of iodo-125-IGF-ll by 40% and by 87% when present at a concentration of 15 nanomol/litre. Unlabeled IGF-I at a concentration of 1,600 nanomol/litre inhibited the specific binding of iodo-125-IGF-ll by 68%. Unlabeled latent TGF 1 inhibited specific binding of iodo-125-lGF-ll by 25% when present at a concentration of 115 nanomol/litre <br><br>
20 Table 1 Effects of unlabeled insulin-like growth factors and unlabelied latent transforming growth factor on binding of radioactively labelled insulin-like growth factor II to human placental microsomal membranes. <br><br>
(Table 1). <br><br>
Radioactivity added <br><br>
40,709 counts per minute (cpm) <br><br>
Total radioactivity bound <br><br>
7.733 cpm (19.0% of the radioactivity added) <br><br>
Blank radioactivity bound <br><br>
2,606 cpm (6.4% of the radioactivity added) <br><br>
Radioactivity bound non-specifically 3,558 cpm (8.7% of the radioactivity added) <br><br>
Radioactivity bound specifically <br><br>
= 7,733 cpm - 3,588 cpm = 4,145 cpm <br><br>
= 10.2% of the radioactivity added <br><br>
21. DEC. 2007 15:59 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 " P. 25/53 <br><br>
16 <br><br>
53.6% of the total radioactivity bound <br><br>
Radioactivity bound in the presence of the following: <br><br>
unlabeled IGF-ll at 1.6 nanomol/litre <br><br>
6,059 cpm unlabeled IGF-II at 15 nanomol/litre <br><br>
4,120 cpm unlabelied IGF-I at 1,600 nanomol/litre 4,905 cpm unlabeled latent TGF 1 at 116 <br><br>
6,717 cpm nanomol/litre <br><br>
"Radioactivity bound specifically is calculated to be the arithmetic difference between the total radioactivity bound and the radioactivity bound non-specifically. <br><br>
Example 1 demonstrates that latent TGF 1 and iodo-125-lGF-l I compete for binding to 5 the @ame site in suspended microsomal membranes prepared from human placenta. IGF-II also inhibits binding of iodo-125-IGF-ll to the same cell membranes. <br><br>
The specific binding of iodo-125-IGF-l I to human placental microsomes in this example is not due to binding to either insulin receptors or type-l IGF receptors, because more than 100-times more unlabelied IGF-I is required to inhibit binding of iodo-125-IGF-ll by 10 as much as achieved by unlabelied IGF-II (Table 1), It is known that IGF-I and IGF-ll have similar affinities for their binding of both insulin receptors and type-1 IGF receptors. It is known that IGF-I has a very poor affinity for binding the CIM6P receptor. <br><br>
The example above demonstrates that iodo-125-IGF-ll binds to CIM6P receptors in human placenta and that lalent TGF 1 inhibits this binding. Accordingly, latent TGF 15 and IGF-ll compete for binding to CIM6P receptors. <br><br>
Example 2 IGF-ll inhibits activation of latent TGF <br><br>
The result of competition between IGF-ll and latent TGF for the CIM6P binding site and its effect on activation of latent TGF can be demonstrated as follows: <br><br>
Human TF1 cells, a monocyte cell line, which express essential components of this 20 system described above ie. CIM6P receptors, urokinase plasminogen activator receptors and secrete abundant latent TGF 1 into the culture media, were cultured in <br><br>
21. DEC. 2007 15:59 PHILLIPS ORMONDE & FITZPATRICK <br><br>
'"NO. 1846 P. 26/53' <br><br>
17 <br><br>
serum-free RPM11640 media (JRH Biosciences) with 2% serum replacement (Sigma). 3,5 x 10"®% -mercaptoethanol (Sigma), 4mM i-glutamine (CSL), 10 g/ml plasminogen (Sigma), 5 g/ml urokinase plasminogen activator (uPA) (Sigma) and 2ng/m! recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) 5 (Leucomax , Schering-Plough). In repiicate wells, monocytes were incubated with either 0,1,12.5,25,50 or 100nM receptor grade IGF-II or 25nM receptor grade Leu^lGF-ll (GroPep, Adelaide). Approximately 1-2x10® monocytes were placed in 500 I media and cultured for 24-26 hours at 37 C in 20% oxygen, 5% carbon dioxide, 75% nitrogen. The cell suspension was then gently aspirated and spun in a centrifuge 10 at 200g for 10 mins at room temperature. The supernatant was collected and frozen at -20 C until assay for active and total TGF -1. Cells were resuspended In Hank's Balanced Salt Solution (HBSS, JRH Biosciences) and counted to determine the effect Of culture on cell proliferation. Supematants were thawed and assayed for TGF -1 using a commercially available human TGF -1 enzyme-linked immunosorbent assay 15 (ELISA) kit (R&D Systems, Inc.) according to the manufacturer's Instructions. Color development was quantified using a BioRad Benchmark microplate reader set at a wavelength of 450nm and corrected to 550nm. The concentration of TGF -1 was calculated automatically by comparing with a standard curve of known concentrations of TGF on the same microplate using BioRad Microplate Manager 5.0 PC Software. 20 Active and total TGF -1 were then calculated per million cells at the end of the culture period. The following table of results, table 2, shows that TF1 monocytes secrete abundant latent TGF -1 into the culture medium and that IGF-II inhibits activation of latent TGF -1. This is shown graphically in figure 2. When uPA is omitted from the culture media there is no activation of latent TGF -1. This provides further evidence 25 that it is the uPA/uPAR/ClM6P receptor system which is responsible for activation of latent TGF on the cell surface. <br><br>
Table 2 The effect of IGF-II on activation of latent TGF by 1x10® TF1 monocytes in vitro. <br><br>
IGF-ll or Leu^lGF-H Total TGF -1 Active TGF -1 as Concentration (pgAnl) %Control <br><br>
0 nmol/L IGF-II <br><br>
1 nmol/L IGF-ll <br><br>
238.49 33.09 229.73 6.33 <br><br>
100.0 <br><br>
4.25 2.60 <br><br>
21. DEC, 2007 16:00 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846 P. 27/53 <br><br>
18 <br><br>
12.5 nmol/L IGF-II <br><br>
252.67 10.41 <br><br>
10.28 6.33 <br><br>
25 nmol/L IGF-II <br><br>
274.70 25.13 <br><br>
5.37 3.55 <br><br>
50 nmol/L IGF-II <br><br>
335.95 <br><br>
0.00 <br><br>
100 nmol/L IGF-II <br><br>
321.08 <br><br>
0.00 <br><br>
25 nmol/L Leu27-lGF-H <br><br>
366.64 <br><br>
12.72 <br><br>
All dab is Mean SEM <br><br>
Hence, we have shown that IGF-II inhibits the activation of latent TGF in vitro. <br><br>
Example 3 Effect of oxygen on cytotrophoblast column formation in vitro <br><br>
It is known that binding of latent TGF to CIM6P receptors present on monocytes that 5 also have uPA receptors results in proteolytic conversion of latent TGF into active TGF (Godar et al. 1999). It is known that cytotrophoblast cells have CIM6P receptors (Rebourcet et al. 1998) and uPA receptors (Fioridon et al. 1999). TGF is known to change cytotrophoblast cells from the invasive type to the fused, terminally differentiated type resulting in formation of multinucleate trophoblast cells called 10 placental bed giant cells. It therefore follows that IGF-ll inhibits activation of latent TGF by cytotrophoblast cells by preventing latent TGF from binding to CIM6P receptors of cytotrophoblast cells. <br><br>
We aiso show herein that during early human pregnancy (7,5-8 weeks) when plscentation is being established and cytotrophoblasts are known to be exposed to low 15 oxygen tensions, they are most Invasive and both IGF-II protein and mRNA expression is increased. The effect of oxygen on IGF-ll mRNA expression and the association of IGF-H mRNA with extravillous cytotrophoblast column formation can be demonstrated thus: <br><br>
Human first trimester placentas were obtained from the Women's and Children's 20 Hospital, North Adelaide, from legal elective terminations of normal pregnancies of 7.5-8 weeks gestation. Placental villous tissue was obtained immediately after vaginal curettage. Villous tissue was washed to remove blood, using cold, sterile PBS, then <br><br>
21. DEC. 2007"16:00 PHILLIPS ORMONDE & FITZPATRICK" <br><br>
NO. 1 846" P. 28/53" <br><br>
19 <br><br>
transported to the laboratory on ice, in HEPES buffered DMEM/F12 supplemented with 10% heat-inactivated fetal bovine serum (HIFBS) and 40 ng/ml gentamycin (GIBCO BRL, Grand Island, NY). The tissue was then rinsed and dissected into 2-3mm pieces in villous culture media (described below) at 37°C, under aseptic conditions. <br><br>
5 Villous culture media consisted of DMEM/F12 (GIBCO BRL, Grand Island, NY) <br><br>
supplemented with: 0.04 mM l-glutamine; 20 ng/ml plasminogen; 20 l/ml antibiotic mix (GIBCO BRL, Grand Island, NY), comprised of 200 units/ml penicillin, 200 g/ml streptomycin and 0.5 g/ml amphotericin; with 10% HIFBS (CSL, Parkville, Vic). <br><br>
Falcon 24-well tissue culture plates (Becton Dickinson, Kranklin Lakes, N J) were 10 coated with 20 I of 1:1 Matrigel :culture media (Matrigel from GIBCO BRL, Grand Island, NY), set in a humid Incubator at 37°C for at least 30 minutes. Villous pieces were weighed, one piece carefully plated per well, and covered with 15 I of 1:1 Matrigel:culture media. The Matrigel was set In an incubator for 20 minutes, before 400 I of culture media was added and the explants cultured overnight, at 37°C in 5% J5 C02 and either 20% or 1 % 02 (equivalent to 98 mmHg or 7-10 mmHg). <br><br>
The following morning (»15 hours), by which time villous tips were adherent to the bottom of the well, 600 I of culture media was added per well, and explants were returned to the same culture conditions. Cultures were maintained for 6-8 days, with media changed every second day. <br><br>
20 Villous cultures were digitally photographed (on an Olympus DP12 camera) immediately before RNA extraction was performed. From these photographs, cytotrophoblast outgrowths were visually scored for their pattern of outgrowth. Absolute counts were recorded for: 1) number of adherent villous tips with outgrowth and 2) number of cell column formations. The number of cell columns per explant were then 25 divided by the total number of tips with outgrowth for that explant. <br><br>
TRIZOL (GIBCO BRL, Grand Island, NY) Was used to extract RNA from villous cultures, according to the manufacturer's protocol for cells grown in a monolayer. For placental villous cultures, 300 I TRiZOL per well was used. RNA concentration was determined by measuring UV light absorbance at 260 ran on a DU-50 30 Spectrophotometer (Beekman Instruments, Irvine, CA). <br><br>
21. DEC. 2007 1 6:00 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846" P. 29/53' <br><br>
20 <br><br>
Aliquots containing 2 g of RNA from each sample were reverse transcribed. The RNA was incubated with random hexamer primers at 65°C for 10 minutes. Tubes were cooled on ice for 5 minutes and ExpandRT, 5x buffer, DTTs (Roche Diagnostics, Indianapolis, IN), and Ultrapure dNTPs (Amersham Pharmacia Biotech, Piscataway, 5 NJ) were added, according to the manufacturer's instructions. The tubes were then incubated at 30°C for 5 minutes, 42°C for 45 minutes, and 95°C for 2 minutes, cooled on Ice and the cDNA was stored at -20°C. <br><br>
Using PrimerExpress software (Applied Biosystems, Poster City, GA), IGF-II oligonucleotide primers were designed to span exons 3 and 4 of the human IGF-II gene 10 (GenBank accession number X03562), giving a predicted amplicon of 90-100 bp. Primers were: forward, 5'-CCC CTC CGA CCG TGC T-3'; reverse, 5'-TGG ATG GAC TGC TTC CAG GTG TCA T-3'. Standard purity primers were made by GensetOligos (Genset Pacific, Llsmore, Australia). <br><br>
Aliquots of 2 I of cDNA were amplified in a reaction mixture (20 I) containing 1 y\ of 15 each IGF-II primer at 10 M/1,10 I of SYBR Green Master Mix (including AmpHTaq® Gold DNA Polymerase, Applied Biosystems, Foster City, CA) and 6 I of molecular grade water (Fluka BioChemika, Messerschm'rttstr, Germany). For the 18s rRNA endogenous control, 2 I of a 1/10 cDNA dilution was amplified in a reaction mixture (20 1) containing 2 I of Universal 18s primer pair mix (Ambion, Austin, TX), 10 I of 20 SYBR Green Master Mix and 7 I of molecular grade water. Three replicates of each cDNA sample were amplified, and negative controls in which cDNA was omitted (water substituted) were included to test for contamination. <br><br>
Using a GeneAmp 5700 thermal cycler (Applied Biosystems, Foster City, CA), the samples were amplified in 1 cycle of 50®C for 2 minutes. 95°C for 10 minutes, followed 25 by 40 cycles of 95#C for 1b seconds and 60°C for 1 minute. The critical threshold (CT) value for each sample was determined with the fluorescence threshold set at 0.150 runs. <br><br>
Aliquots of 7 I of PCR product were fractionated by electrophoresis, in parallel with pUC19 molecular weight markers, in a 2% agarose gel (Sigma Chemical Co, St Louis. 30 MO), stained with ethidium bromide. Bands were visualised under UV light, and digitally photographed. <br><br>
21. DEC. 2007 16:01 PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1 846 P. 30/53 <br><br>
21 <br><br>
Figure 3 shows graphically that the number of cytotrophoblast cell columns per growing placental villous tip is increased by culture in hypoxic conditions. <br><br>
Figure 4 shows graphically the ranked Ct medians were transformed to show IGF-II mRNA expression for each treatment group relative to the median for the calibrator 5 (control)group for the hypothesis being tested, given as 100%, <br><br>
Thus exposure of extravillous explants to hypoxic culture conditions increases the number of cytotrophoblast ceil columns and increases extravillous cytotrophoblast invasive behaviour. In addition, culture in 1% oxygen induces a 7-fold increase in IGF-II mRNA synthesis in placentas of 7-8.5 weeks which will greatly increase their capacity 10 for invasion of the uterine decidua and subsequent placental differentiation. IGF-II mRNA was positively correlated with the proportion of outgrowing villous tips that formed cytotrophoblast cell columns (r=-0.296, n=65, p=0.017). <br><br>
Treatment with IGF- II thus promotes and maintains the invasive state of cytotrophoblast cells by inhibiting their fusion due to preventing activation of latent 15 TGF by binding to CIM6P receptors of cytotrophoblast cells. Alternatively, culture in low oxygen conditions (less than 3%) stimulates IGF-II production, thus adjusting the level of IGF-II in the cellular environment to thereby maintain the mesenchymal migratory phenotype. <br><br>
Example 4 IGF-ll enhances placental development in vivo <br><br>
20 Enhanced invasion of cytotrophoblasts during pregnancy results in a more functional placenta because the circumferential expansion of the placenta as it grows, as well as acquisition of an adequate utero-placental blood supply, depend on trophobiast invasion of the decidua. It has previously been shown that In pregnant guinea pigs the concentration of IGF-II in maternal blood during pregnancy is a predictor of the 25 structural development of the placenta, parameters of which correlate with placental function and fetal weight and that this is a particularly strong association in early to mid-gestation when the placenta is in its hyperplastic growth phase (Roberts et al., 2001). Therefore we also show herein the effect of treatment of the pregnant mother with exogenous IGF-ll on placental growth and development. <br><br>
30 We obtained 30 eight week old C57B1/6 female mice from the University of Adelaide Medical School Animal House and divided them into three groups of similar weight. <br><br>
21 DEC, 2007 16:01 PHILLIPS ORMONDE & FITZPATRICK <br><br>
"NO. 1846 P. 31/53 <br><br>
22 <br><br>
Females were mated with 9-10 week Batb/C male mice and checked for the presence of a vaginal copulatory plug the next morning. The day of the copulatory was designated as day 1 of pregnancy. At midday on day 2 of pregnancy mice were treated with either 0,12.5 or 25//g/day IGF-II, which translates to 0, 0.5 or 1.0mg/kg/day IGF-II 5 based on weight at mating, in 0.1mmol/L acetic acid delivered by a subcutaneous osmotic minipump (Alzet 1007D) from days 2-10 of pregnancy. Osmotic minipumps were inserted subcutaneously on the back under anaesthesia and strict aseptic conditions. Anaesthesia was induced with 3% halothane in oxygen using an anaesthetic machine and maintained with 2% halothane. The lower back was shaved 10 and swabbed and a 1,0cm transverse incision was made. An artery clamp was used to make a long subcutaneous pocket higher up on the back such that when the minipump was inserted it lay well away from the incision which was then closed with 2 wound clips. Mice were given one or two puffs of pure oxygen after which they regained consciousness within one minute. Pumps were not primed so as to delay the initiation 15 of pumping by 4-6 hours. Osmotic minipumps delivered 0,12.5 or 25jug/day IGF-II, at a flow rate of 0J52 l/h which was equivalent to 0,0.5 or 1.0 mg/kg/day IGF-II based on body weight at surgery. Mice were killed by ether overdose on day 18 of pregnancy (term -19 days). Blood was taken in heparinized tubes and centrifuged. Plasma was frozen at -20 C. Placentas and fetuses were excised from the uterus and weighed. The 20 mother's carcass minus the uterus and minipump was weighed. <br><br>
The results, as depicted in figures 5-13 indicate that treatment of pregnant mice between days 2 and 10 of pregnancy increased placental weight at day 18 of gestation by 7.5 % (p<0.05) and 9.6 % (pO.OS) by treatment with 12.5 or 25/zg/day IGF-II, respectively (figure 5). The distribution of placenta! weights across litters was skewed to 25 the right by treatment with IGF-ll. The percentage of placentas that weighed more than iZOmg was 3.1% in control mice, 25.8% in mice treated with the 12.5//g/day IGF-H, (p<0.0001) and 29.6% in mice treated with the 25^/g/day IGF-II (p<0.0001) (figure 6). <br><br>
Thus treatment of the mother with slow release IGF-II during the first half of pregnancy enhances placental growth. Treatment with 25^g/day IGF-II increased fetal weight by 30 4.1 % (p<0.05) (figure 7). The distribution of fetal weights across litters was skewed to the right by treatment with iGF-ll. The percentage of fetuses weighing more than 110Qmg was 21.5% in control mice, 27.4% in mice treated with 12.5//g/day IGF-ll (NS) and 53.6% in mice treated with the 25//g/day IGF-ll (p<0.0001) (figure 8). <br><br>
21. DEC. 2007 16:01 <br><br>
PHILLIPS ORMONDE & FIT2PATRICK <br><br>
'NO. 1846—P. 32/53 <br><br>
23 <br><br>
There was no difference in maternal weight gain or net carcass weight following treatment with IGF-II during pregnancy. Maternal weight gain was only related to litter size. This suggests that treatment with IGF-II at these doses does not increase cell proliferation in the mother. <br><br>
5 In a second replicate of 30 pregnant mice, treatments were identical to the first replicate except that the osmotic minipumps used (Alzet 1002} delivered the growth factor or vehicle at 0.22 l/ft from days 2*18 of pregnancy when the animals were killed and fetal and placental weights recorded. The daily dose delivered was identical to that of the first replicate, either 0,12.5 or 25pg/day IGF-II, which translates to 0,0.5 or 10 1.0mg/kg/day IGF-ll based on weight at mating. <br><br>
Treatment of pregnant mice with IGF-II between days 2 and 18 of pregnancy reduced placental weight In the high dose group by 4.8% (p-0.001) (figure 9), increased the thickness of the placenta by 5,6% (p=0.026) (figure 10). The distribution of fetal weights across litters was altered by treatment of the mother with IGF-II with a significant skew 15 to the right in the 25//g/day IGF-II group (p<Q.0001) (figure 11). The distribution of placental weights across litters was also altered by treatment with IGF-II with a significant skew to the left in both treatment groups (p<0.0001) (Figure 12) <br><br>
In addition treatment of pregnant mice with 25//g/day IGF-II increased the ratio of fetal weight to placental weight by 6.8% (p=0.026) (figure. 13). This is an indicator of 20 placental functional capacity. A higher ratio suggests that more grams of fetus are produced for every gram of placenta. Thus the placenta is more efficient at extracting nutrients from the mother and transporting them to the fetus. Thus we have shown that treatment with IGF-II of the pregnant mouse improves placental and fetal development. However, treatment with IGF-II for the first half of pregnancy appears to be more 25 efficacious than treatment throughout pregnancy with the same dose. It will be appreciated that the mice in the second replicate received the same amount of IGF-ll each day from days 2-18 of pregnancy during which time maternal body weight was increasing. Hence the dose/day/kg was reducing, particularly in the second half of pregnancy when maternal weight gain is increasing. In addition, given that 30 cytotrophoblasts are at their most invasive in the first half of pregnancy it may be most desirable to treat during this phase and may even have undesirable effects if continued throughout pregnancy. <br><br>
"21. DEC. 2007~16:02 "PHILLIPS. ORMONDE & FITZPATRICr <br><br>
-NO. 1846" ""P. 33/53"— <br><br>
24 <br><br>
It will be appreciated that the mice used in this experiment had norma! placental IGF-II production. It is known thai when the IGF-ll gene is ablated in mice there is a considerable reduction in growth of the placenta and the fetus. It could be expected in embryos and/or their parents diagnosed with lower than normal capacity for IGF-ll synthesis, the restoration of IGF-II to normal levels would have a still greater effect on placental development and hence fetal growth than is observed herein. <br><br>
There was no difference in maternal weight gain or net carcass weight following treatment with IGF-ll during pregnancy. Maternal weight gain was only related to litter size. Maternal net carcass weights were 24.1 0.4g, 24.2 0,4g and 24,9 0.4g for 10 control, 0.5 mg/kg/day IGF-II and 1.0mg/kg/day IGF-II (p-0.262), respectively. This suggests (hat treatment with IGF-II throughout pregnancy at these doses does not Increase cell proliferation in the mother, <br><br>
The regulation of cytotrophoblast behaviour by IGF-II provides support for the notion that central of the cell exposure to IGF-ll and latent TGF/? will affect stem cell 15 (embryonic and adult) differentiation referred to hereinabove. <br><br>
The invention has been described by way of example. The examples are not, however, to be taken as limiting the scope of the invention in any way. Modifications and variations of the invention such as would be apparent to a skilled addressee are deemed to be within the scope of the invention. <br><br>
20 Publications Cited <br><br>
Bennett ST & Todd JA (1996) Human type I diabetes and the Insulin gene: principles of mapping polygenes. Annu Rev Genetics 30:343-370. <br><br>
Bermingham J, Jenkins D, McCarthy T, O'Brien M (2000) Genetic analysis of insulin-like growth factor ll and HLA-G in pre-eclampsia. Biochem Soc Trans 28:215-9. <br><br>
25 Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski & Post M (2000) Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 105,577-567. <br><br>
'21. DEC, 2007 16:02 <br><br>
PHILLIPS ORMONDE &'FITZPATRICK" <br><br>
—NO. 1 846 P- 34/53' <br><br>
25 <br><br>
Djurovic S, Schjetlein R, Wisloff F, Haugen G, Husby H, Berg K (1997) Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia. Clin Genet 52:371-376 <br><br>
Dommisse J & Tiltman AJ (1992) Placental bed biopsies in placental abruption. Br J 5 Obsiel Gynaecol 99:651-4 <br><br>
Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL (1999) Reciprocal positive regulation of hypoxia-inducible factor 1 and insulin-like growth factor 2. Cancer Research 59:3915-3918. <br><br>
Floridon C, Nielsen 0, Holund B, Sunde L, Westergaard JG, Thorns 5G & Teisner B 10 (1999) Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. Placenta 20:711-721 <br><br>
Francis GL, McNeil K, Wallace JC, Ballard FJ & Owens PC (1989) Sheep insulin-like growth factors I and II: sequences, activities and assays. Endocrinology 124:1173-1183 <br><br>
15 Gargosky SE, Moyse KJ, Walton PE, Owens JA, Wallace JC, Robinson JS, Owens PC 1990 Circulating levels of insuiin-like growth factors increase and molecular forms of their serum binding porteins change with human pregnancy. Biochemical and Biophysical Research Communications 170:1157-1163 <br><br>
Genbacev O, Zhou Y, Ludlow JW & Fisher SJ (1997) Regulation of human plaoental 20 development by oxygen tension. Science 277,1669-1672. <br><br>
Godar S, Horesji V, Weidle UH, Binder BR, Hansmann C & Stockinger H (1999) M6P/IGF!keceptor complexes urokinase receptor and plasminogen for activation of transforming growth factor betel. Eur J Immunol 29:1004-1013 <br><br>
Graham CH & Lata PK (1991) Mechanism of control of trophoblast invasion tn situ, J 25 Cell Physiol 148:228-234 . <br><br>
Guidice LC, Mark SP & Irwin JC (1998) Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. J Reprod Immunol 39,133-148. <br><br>
21. DEC. 2007 16:02 <br><br>
PHILLIPS ORMONDE & FITZPATRICK <br><br>
NO. 1846" P. 35/53 <br><br>
26 <br><br>
Hamilton GS, Lyslak JJ, Han VKM & Lala PK (1998) Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-I1 and IGF-binding protein (1GFBP)-1. Exp Cell Res 244:147-156 <br><br>
Huang LE, Arany 2, Livingston DM & Bunn HF (1996) Activation of hypoxia-inducible 5 transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271.32253-32259. <br><br>
Irwin JC, Suen LF, Martina NA, Matk SP & Guidice LC (1999) Role of the IGF system in trophoblast invasion and pre-eclampsia. Human Reprod 14:90-96 <br><br>
Khong TY, De Wolf F, Robertson WB & Brosens I (1986) Inadequate maternal vascular 10 response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age Infants. Br J Obstet Gynaecol 93:1049-1059 <br><br>
Khong TY, Liddell HS, Robertson WB (1987) Defective haemochorial placentation as a cause of miscarriage: a preliminary study. Br J Obstet Gynaecol 94(7):649-55. <br><br>
Lala PK & Graham CH (1990) Mechanisms of trophoblast invasiveness and their 15 control: the role of proteases and protease inhibitors. Cancer Metastasis Rev 9(4):369-79 <br><br>
Morrish DW, Dakour J & Li H (1998) Functional regulation of human trophoblast differentiation. J Reprod Immunol 39:179-195 <br><br>
Odell SD & Day INM (1988) Molecules in focus; insulin-like growth factor II. lot J 20 Blochem Cell Biol 30:767-771 <br><br>
Ong KK, Phillips Dl, Fall C, Pouiton J, Bennett ST, Golding J, Todd JA, Dunger DB (1999) The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet 21:262-3, <br><br>
Owens PC, Brinsmead MW, Waters MJ & Thorbum GD (1980) Ontogenic changes in multiplication-stimulating activity binding to tissues and serum somatomedin-like 25 receptor activity in the ovine fetus. Biochem Biophys Res Commun 96:1812-1820 <br><br>
21. DEC. 2007 16:02 PHILLIPS ORMONDE & FITZPATRICK' <br><br>
'NO. 1846—P. 36/53 <br><br>
27 <br><br>
Owens PC, Waters MJ, Thorburn GD 6. Brinsmead MW (1985) Insulin-tike growth factor receptor in fetal lamb liver: characterization and developmental changes. Endocrinology 117:982-92 <br><br>
Pijnenborg R, Bland JM, Robertson WB & Brosens I (1983) Uteroplacental arterial 5 changes related to interstitial trophoblast migration in early human pregnancy. Placenta 4:397-414 <br><br>
Rebourcet R, de Ceuninck F, Deborde S, Willeput J & Ferre F (1998) Differential distribution of binding sites for 12Sl-insulin-like growth factor II on trophoblast membranes In human term placenta. Biol R0prod 58:37-44. <br><br>
10 Schilling B & Yeh J (2000) Transforming growth factor beta(1 j, -beta(2), -beta(3) and their type I and II receptors in human term placenta. Gynecol Obstet Invest 50:19-23. <br><br>
Tropepe V, Hitoshl S, Sirard C, Mak TW, RossantJ & van der Kooy D (2001) Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron 30:65-78. <br><br>
15 Wang GL, Jiang BH, Rueand EA & Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-hellx-toop-helix-PAS heterodimer regulated by cellular 02 tension. Proc Natl Acad Scl USA 92,5510-5514. <br><br>
Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. 20 EmboJ l7(17):50B5-94. <br><br></p>
</div>
Claims (8)
1. Use of one or more of IGF-II, a precursor of IGF-II, an isomer of IGF-II, and an analogue of IGF-II in the preparation of a medicament for administration to a female human<br><br> 5 to prevent and/or treat one or more of implantation failure, recurrent spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and placental abruption,<br><br>
2. Use according to claim 1, wherein the administration to the female human includes administration to the female human in early to mid pregnancy,<br><br> 10<br><br>
3. Use according to claims 1 or 2, wherein the administration to the female human is by way of a subcutaneous delivery device and/or a vaginal pessary.<br><br>
4. A method of promoting implantation of a non-human embryo in a non-human female 15 mammal and/or promoting placentation in a non-human female mammal, the method including administering to the female mammal an effective amount of one or more of IGF-II, a precursor of IGF-II, an isomer of IGF-ll, and an analogue of IGF-H.<br><br>
5. A method of preventing and/or treating one or more of implantation failure, recurrent 20 spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and placental abruption in a non-human female mammal, the method including administering to the non-human female mammal an effective amount of one or more of IGF-II, a precursor of IGF-II, an isomer of IGF-ll, and an analogue of IGF-II.<br><br> 25
6. A use according to claim 1, substantially as herein described with reference to the accompany drawings.<br><br>
7. A method of promoting implantation of a non-human embryo in a non-human female mammal and/or promoting placentation in a non-human female mammal, substantially as<br><br> 30 herein described with reference to the accompany drawings.<br><br>
8. A method of preventing and/or treating one or more of implantation failure, recurrent spontaneous miscarriage, pre-eclampsia, intrauterine growth restriction, and placental abruption in a non-human female mammal, substantially as herein described with reference<br><br> 35 to the accompanying drawings,<br><br> </p> </div>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR7331A AUPR733101A0 (en) | 2001-08-30 | 2001-08-30 | Regulation of cell differentiation and cell migration |
NZ531362A NZ531362A (en) | 2001-08-30 | 2002-08-30 | Regulation of cytotrophoblast cell differentiation and cell migration |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ564732A true NZ564732A (en) | 2009-05-31 |
Family
ID=3831283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ531362A NZ531362A (en) | 2001-08-30 | 2002-08-30 | Regulation of cytotrophoblast cell differentiation and cell migration |
NZ564732A NZ564732A (en) | 2001-08-30 | 2002-08-30 | Regulation of cytotrophoblast cell differentiation and cell migration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ531362A NZ531362A (en) | 2001-08-30 | 2002-08-30 | Regulation of cytotrophoblast cell differentiation and cell migration |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1432790B1 (en) |
AT (1) | ATE519497T1 (en) |
AU (1) | AUPR733101A0 (en) |
CA (1) | CA2458972A1 (en) |
NZ (2) | NZ531362A (en) |
WO (1) | WO2003018781A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0483866A (en) * | 1990-07-27 | 1992-03-17 | Mitsubishi Electric Corp | Laser vapor deposition device |
-
2001
- 2001-08-30 AU AUPR7331A patent/AUPR733101A0/en not_active Abandoned
-
2002
- 2002-08-30 CA CA002458972A patent/CA2458972A1/en not_active Abandoned
- 2002-08-30 WO PCT/AU2002/001226 patent/WO2003018781A1/en not_active Application Discontinuation
- 2002-08-30 NZ NZ531362A patent/NZ531362A/en not_active IP Right Cessation
- 2002-08-30 EP EP02766939A patent/EP1432790B1/en not_active Expired - Lifetime
- 2002-08-30 NZ NZ564732A patent/NZ564732A/en not_active IP Right Cessation
- 2002-08-30 AT AT02766939T patent/ATE519497T1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1432790A4 (en) | 2006-08-30 |
WO2003018781A1 (en) | 2003-03-06 |
ATE519497T1 (en) | 2011-08-15 |
EP1432790B1 (en) | 2011-08-10 |
NZ531362A (en) | 2008-02-29 |
AUPR733101A0 (en) | 2001-09-20 |
EP1432790A1 (en) | 2004-06-30 |
CA2458972A1 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kawamura et al. | Brain-derived neurotrophic factor promotes implantation and subsequent placental development by stimulating trophoblast cell growth and survival | |
Forbes et al. | Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta | |
Choi et al. | Administration of visfatin during superovulation improves developmental competency of oocytes and fertility potential in aged female mice | |
Thomas et al. | How to make a good oocyte: an update on in‐vitro models to study follicle regulation | |
Jeong et al. | Epidermal growth factor stimulates proliferation and migration of porcine trophectoderm cells through protooncogenic protein kinase 1 and extracellular-signal-regulated kinases 1/2 mitogen-activated protein kinase signal transduction cascades during early pregnancy | |
US20070190056A1 (en) | Muscle regeneration compositions and uses therefor | |
Audette et al. | Dexamethasone stimulates placental system A transport and trophoblast differentiation in term villous explants | |
US20210355436A1 (en) | Precursory regulatory cytotrophoblast cells and uses thereof | |
Thieme et al. | Insulin growth factor adjustment in preimplantation rabbit blastocysts and uterine tissues in response to maternal type 1 diabetes | |
Fujimoto et al. | Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects | |
Pellicer et al. | Ovarian follicular dynamics: from basic science to clinical practice | |
KARABULUT et al. | Growth promoting effects of human placental lactogen during early organogenesis: a link to insulin-like growth factors | |
US7244707B2 (en) | Regulation of cytotrophoblast cell differentiation and cell migration | |
EP1432790B1 (en) | Regulation of cytotrophoblast cell differentiation and cell migration | |
AU2002331424A1 (en) | Regulation of cytotrophoblast cell differentiation and cell migration | |
AU2008203217A1 (en) | Regulation of cytotrophoblast cell differentiation and cell migration | |
Ubaldi et al. | Implantation in patients over 40 and raising FSH levels—A review | |
US20230338529A1 (en) | Compositions for altering a microglial cell, and methods of use therefore | |
Lee et al. | Sodium nitroprusside treatment during the superovulation process improves ovarian response and ovarian expression of vascular endothelial growth factor in aged female mice | |
Calo et al. | VPAC1 and VPAC2 receptor deficiencies negatively influence pregnancy outcome through distinct and overlapping modulations of immune, trophoblast and vascular functions | |
Mou et al. | Involvement of the Increased SF-1 Expression Induced by DNA Hypomethylation through DNMTs in Endometrial Decidualization | |
Brodeur et al. | The embryo in reproductive failure: immunological view | |
Donovan | Investigating Thyroid Hormone Transport and Regulation in Chorionic Somatomammotropin RNAi Models of Intrauterine Growth Restricted Pregnancies | |
Lee | Rescue for Primary Ovarian Insufficiency | |
Chen | Regulation of protein metabolism in skeletal muscle of low-birth-weight neonatal pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
LAPS | Patent lapsed |